Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma
Clinical Lymphoma Myeloma and Leukemia · 2024-02 · 24 (2) · 105-121
DOI: 10.1016/j.clml.2023.09.007 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2024-02. Verfasst von Francesc Bosch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: fbosch@…. Hauptthemen laut MEDLINE: Lymphoma, Follicular, Antineoplastic Agents, Antibodies, Bispecific, Benzamides. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: F. Hoffmann-La Roche.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vall d'Hebron University Hospital, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. Electronic address: fbosch@vhebron.net.
- Princess Margaret Cancer Centre, Toronto, ON, Canada.
- Department of Haematology and Bone Marrow Transplantation, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece.
- F. Hoffmann-La Roche, Basel, Switzerland.
- Genentech, South San Francisco, CA.
- The University of Texas MD Anderson Cancer Center, Houston, TX.
Förderung
- F. Hoffmann-La Roche
Zitieren
APA
Bosch, F., Kuruvilla, J., Vassilakopoulos, T. P., Maio, D. D., Wei, M. C., Zumofen, M. B., & Nastoupil, L. J. (2024). Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia, 24(2), 105-121. https://doi.org/10.1016/j.clml.2023.09.007
Vancouver
Bosch F, Kuruvilla J, Vassilakopoulos TP, Maio DD, Wei MC, Zumofen MB, et al. Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma. Clinical Lymphoma Myeloma and Leukemia. 2024;24(2):105-121. doi:10.1016/j.clml.2023.09.007
BibTeX
@article{Bosch2024,
author = {Bosch, Francesc and Kuruvilla, John and Vassilakopoulos, Theodoros P and Maio, Danilo Di and Wei, Michael C and Zumofen, Marie-Helene Blanchet and Nastoupil, Loretta J},
title = {Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2024},
volume = {24},
number = {2},
pages = {105--121},
doi = {10.1016/j.clml.2023.09.007}
}
EUVIMED